Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Upbeat On Risperidone Results

Collaborating With MedinCell On Long-Acting Injectable Version

Executive Summary

Following positive trial results, Teva says it is exploring options with the US FDA for filing a long-acting subcutaneous injectable version of risperidone that it is developing with MedinCell.

You may also be interested in...



Teva Targets Risperidone LAI In H1 2023 Following Earlier FDA Snub

Teva maintains that the clinical data package looks sounds for it and partner MedinCell’s proposed 505(b)(2) hybrid risperidone long-acting injectable product, as the firms look to muscle in on the multi-billion-dollar LAI schizophrenia market next year.

Teva Moves Forward With LAI Olanzapine Trials

Teva is starting Phase III trials for a long-acting injectable formulation of olanzapine, partner MedinCell has revealed. The move comes after the pair were knocked back on their partnered risperidone product earlier this year by the US FDA, with a new expected launch date for that product now also disclosed by the French company.

Teva Denied On LAI Risperidone But Expected To Bounce Back ‘Quickly’

Development partners Teva and MedinCell are not licking their wounds after being denied USFDA approval for their proposed 505(b)(2) hybrid risperidone long-acting injectable product.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150567

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel